Abstract
Laterality defects are defined by perturbations in the usual left-right asymmetry of organs. Due to low known genetic etiology of congenital heart disease (CHD) cases (less than 40%), we used a digenic model approach for the identification of contributing variants in known laterality defect genes (N = 115) in the exome/genome sequencing (ES/GS) data from individuals with clinically diagnosed laterality defects. The unsolved ES/GS data were analyzed from three CHD cohorts: Baylor College of Medicine-Genomics Research to Elucidate the Genetics of Rare Diseases (BCM-GREGoR; N = 247 proband ES), Gabriella Miller Kids First Pediatric Research program (Kids First; N = 158 trio GS), and Pediatric Cardiac Genomics Consortium (PCGC; N = 163 trio ES), and trans-heterozygous digenic variants were identified in 2.8% (inherited digenic variants in 0.4%), 8.2%, and 13.5% cases respectively, which was significantly higher as compared to 602 control trios provided by the 1000 Genomes Project (p = 0.001, 1.4e-07, and 8.9e-13, respectively). Trans-heterozygous digenic variants were also identified in 0.4%, and 1.4% cases with non-laterality CHD in Kids First and PCGC datasets, respectively, which was not statistically significant as compared to control trios (p = 1, and 0.059, respectively). Altogether, in laterality cohorts, 23% of digenic pairs were in the same structural complex of motile cilia. Out of 39 unique digenic pairs in laterality CHD, 29 are more likely to be potential digenic hits as predicted by DiGePred tool. These findings provide further evidence that digenic epistatic interaction can contribute to the complex genetics of laterality defects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the US National Human Genome Research Institute/National Heart Blood Lung Institute jointly funded Baylor Hopkins Center for Mendelian Genomics (UM1HG006542), by the National Institutes of Health (NIH) (5R01 HD039056, 5R01 HL091771), by the Genomic Research Elucidates the Genetics of Rare disease (GREGoR) program (UM1 HG011758) to J.E.P., J.R.L. and R.A.G., and by the National Institute of Neurological Disorders and Stroke (NINDS R35 NS105078) to J.R.L.. For the Kids First study, dbGaP data with accession phs002517.v4.p2 was used. The data from this study phs002517 was made available pre-publication without embargo to support rapid and collaborative research in pediatric cancer via the NCI's Cancer Research Data Commons (https://datacommons.cancer.gov). This availability is made possible with the support of NCI's Childhood Cancer Data Initiative (grant No. 3P30CA082103-21S9) and Gabriella Miller Kids First Pediatric Research Program (X01 CA267587). Initial data generation efforts and coordination costs were supported by a number of philanthropic and industry partners with further details at cbtn.org. A.R. was supported by Pediatric Cardiac Genomics Consortium and Cardiovascular Development Data Resource Center 2023 Fellows Program (AGT012018) at the University of Texas at Health Science Center at Houston, TX. Z.C.A was supported by the TOPMed NHLBI fellowship and Simons Foundation pilot award (AGT011737).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Baylor College of Medicine approved research study protocol (IRB approval number: H-1843) and Baylor Genetics (BG) for clinical exomes (IRB approval number: H-48014) for Baylor College of Medicine-Genomics Research to Elucidate the Genetics of Rare Diseases (BCM-GREGoR)data. PCGC subjects were recruited to the Congenital Heart Disease Genetic Network Study of the Pediatric Cardiac Genomics Consortium (CHD GENES: ClinicalTrials.gov identifier NCT01196182). The institutional Review Boards of Boston's Children's Hospital, Brigham and Women's Hospital, Great Ormond Street Hospital, Children's Hospital of Los Angeles, Children's Hospital of Philadelphia, Columbia University Medical Center, Icahn School of Medicine at Mount Sinai, Rochester School of Medicine and Dentistry, Steven and Alexandra Cohen Children's Medical Center of New York, and Yale School of Medicine approved the protocols. All subjects or their parents provided informed consent. Kids First project represents a subset of the PCGC data so CHD subjects were recruited as per PCGC study protocol.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets used and/or analyzed during the current study are available in the supplementary data.
